INTRODUCTION
Hematopoietic cell transplantation (HCT) is a curative treatment for a broad spectrum of hematopoietic diseases including acute and chronic leukemias, myelodysplastic syndromes (MDS), lymphomas, aplastic anemia, immune disorders and other congenital disorders of metabolism. [1] [2] [3] [4] International data on HCT activity are collected by a number of registries including the Center for International Blood and Marrow Transplant Research (CIBMTR), the European Group for Blood and Marrow Transplantation (EBMT) and the Asia-Pacific Blood and Marrow Transplantation Group (APBMT). [1] [2] [3] The CIBMTR collects HCT data from over 1566 participating centers worldwide. 1 The EBMT collects HCT data from more than 550 centers in Europe 2 and also runs an annual activity survey. 2, 3 The APBMT collects allogeneic HCT data from over 432 participating centers in the Asia-Pacific region. 4 Data from these registries indicate that there are regional differences in transplant indications and donor availability.
There is a survey from pediatric patients in China, 5 but no nationwide survey of the entire population of transplant patients. The Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) was established in 2007 and collects data every 6 months. In China, increasing numbers of haploidentical donor (HID) HCT are performed. To understand the patient and donor pools, we performed a survey of trends and highlighted differences from Western reports. Our survey of HCT activity in China involves an 8-year period and is based on available databases to provide an overview of the current state of HCT in China.
MATERIALS AND METHODS

Data collection
From January 2008, the Stem Cell Application Section of the Hematology Branch of the Chinese Medical Association organized a nationwide registration of HCT. Participating HCT teams were required to report their data by Excel form to the CBMTRG every 6 months. The data included transplant numbers, disease, patients' gender and age, conditioning regimen, donor type and stem cell source. This was a retrospective study focusing on data collected from HCT centers in China during the period from January 2008 to June 2016. The teams involved in this study are listed in the Supplementary Appendix in alphabetical order by the name of the hospital.
RESULTS
Numbers of participating teams and transplants
Over the survey period, additional centers joined the CBMTR. There were 27 participating transplant teams in the first half of 
Allogeneic HCT trends
Patients' age and gender. Forty percent of the allogeneic HCT patients were female and 60% were male. The number of pediatric patients (⩽18 years of age) was 4826 (29.0%) and elderly patients (450 years of age) 916 (5.5%) (Figure 2d ). There were 72 patients 460 years of age (0.4%). The ratio of pediatric and elderly patients increased annually ( Figure 3 ). In the latest report, TBI-based conditioning was applied in 11.4% of allogeneic HCT patients, non-TBI conditioning was applied in 89.6%.
Disease indications. HCT centers performed allogeneic HCTs for both malignant and non-malignant diseases. There were more transplants performed for malignant (~82%) compared to non-malignant (~8%) conditions (Figure 2c ). The distributions of diseases leading to allogeneic HCT between January 2008 and June 2016 were: AML (34%), ALL (26%), severe aplastic anemia (SAA) (11%), MDS (9%), CML (8%), non-Hodgkin's lymphoma (3%) and other diseases (2%) (Figure 2c ). In the latest registry, among allogeneic HCTs, AML was the most common reason (35%), followed by ALL (25%), MDS (9%) and CML (3%). For non-malignant conditions, allogeneic HCT was performed most for SAA (15%), followed by hemoglobinopathy (4%).
The number of allogeneic HCTs for most types of hematological malignancies, including AML, ALL and MDS, has been increasing. The number of cases of allogeneic HCT for SAA has also increased annually, from 59 cases ( in HID HCT. We also found that the number of HIDs for SAA increased. There are more allogeneic than autologous HCTs in the database. This is similar to a report from the American Society for Blood and Marrow Transplantation, but differs from reports from EBMT and CIBMTR that found more autologous HCT. [1] [2] [3] [4] There are many reasons contributing to the increased number of allogeneic HCTs. One was an increase in the number of reporting teams and mean transplant activity per team (from 39 to 69 HCTs per team). A second reason is expansion of the donor pools because the unrelated volunteer donor bank and cord blood bank were enlarged. The success of HID HCT has brought in a new era of 'everyone has a donor' to the real world. The third reason is that patients eligible for HCT increased because older patients could receive a reduced intensity conditioning regimen and the list of disease indications for HCT increased.
In a consensus statement on allogeneic HCT in China published in 2014, the indications include HID HCT for selected subgroups of low-risk AML in CR1, intermediate-risk AML in CR1, Philadelphia (Ph)+ ALL, adult standard risk ALL-CR1/MDS/CML-AP, as well as high-risk leukemia and CML-BC. 6 These indications for HCT differ markedly from those in the National Comprehensive Cancer Network guidelines.
7-10 However, current clinical practice is supported by the results of HID HCT and clinical trials organized by Huang et al. (some trials are listed in Table 1 ).
11-25
The AML patient subgroup classified in the low-risk karyotype by the World Health Organization stratification system, obtained benefit from allogeneic HCT in CR1 status following re-stratification by applying risk-directed therapy based on MRD. In a trial registered at http://www.chictr.org.cn/enIndex.aspx as #ChiCTR-OCH-12002406, 13 the high-risk group was defined as those patients not achieving major molecular remission (MMR) after the second consolidation therapy or those exhibiting the loss of MMR within 6 months of achieving MMR. The low-risk group was defined as patients who achieved MMR after the second consolidation therapy and Abbreviations: AP = accelerated phase; BC = blast crisis; CP = chronic phase; CT = chemotherapy; HCT = hematopoietic cell transplantation; HID = haploidentical donor; HR = high risk; HSCT = hematopoietic stem cell transplantation; IM = imatinib; IR = intermediate risk; LFS = leukemia-free survival; LR = low risk; MDS = myelodysplastic syndrome; MR = molecular response; MRD = matched-related donor; OS = overall survival; ph = Philadelphia chromosome[t(9;22)]; RR = relapse rate; SAA = severe aplastic anemia; SR = standard risk; T_ALL = T-cell ALL; TKI2 = second-generation TKI. *The difference is statistically significant. maintained MMR for 6 months. Risk-directed therapy included recommending allogeneic HCT for high-risk patients and chemotherapy/autologous stem cell therapy for low-risk patients. Similar results were observed with inv(16) AML. 14 A CBFB-MYH11 level of 0.2% after course 2 consolidation was used to define a poor molecular response. Compared with chemotherapy/autologous stem cell therapy, allogeneic stem cell therapy decreased the 3-year cumulative incidence of relapse and improved the disease-free survival and overall survival of patients with a poor molecular response, but did not improve the outcome of patients with good molecular response. Treatment based on minimal residual diseasedirected risk stratification may improve the outcome of t(8;21) AML or inv(16) AML in CR1 and is recommended in practice. 13, 14 Adult Ph ( − ) ALL patients with high-or low-risk can obtain benefit from HID HCT in CR1. [16] [17] [18] [19] [20] Thus, Ph(+) ALL remains an important indication for allogeneic HCT in the era of treatment with tyrosine kinase inhibitors.
Allogeneic HCT, combined with tyrosine kinase inhibitor maintenance therapy after HCT, can reduce the relapse rate and improve disease-free survival time. 21 Overall, allogeneic HCT is recommended for all ALL patients except standard risk pediatric patients. 6 There has been a notable decrease in HCT for CML in the chronic phase in Europe since 2000 due to the use of tyrosine kinase inhibitors. 26 This trend has been delayed several years in China, as CML was 22.7% among allogeneic HCT in 2008. Tyrosine kinase inhibitors are expensive and need to be given to patients for a long period. The consideration of cost effectiveness between these two highly expensive treatments, and the desire for a cure, affected the trends for HCT.
On the basis of results from a cohort study demonstrating that allogeneic HCT is superior to first-and second-generation tyrosine kinase inhibitors for accelerated phase and blastic crisis patients, [22] [23] [24] [25] the consensus statement in China published in Abbreviations: aGvHD = acute GvHD; AL = acute leukemia; AP = accelerated phase; BC = blast crisis; CBMTR = Chinese Blood and Marrow Transplantation Registry Group; CBT = cord blood transplantation; CP = chronic phase; FFS = failure free survival; HID = haploidentical donor; HR = high risk; HSCT = hematopoietic stem cell transplantation; IM = imatinib; IR = intermediate risk; IST = immunosuppressive therapy; LFS = leukemia-free survival; LR = low risk; MDS = myelodysplastic syndrome; MRD = matched-related donor; MR = molecular response; NRM = non-relapse mortality; OS = overall survival; ph = Philadelphia chromosome[t(9;22)]; RR = relapse rate; SAA = severe aplastic anemia; T_ALL = T-cell ALL; TKI2 = second-generation TKI; URD = unrelated donor. *The difference is statistically significant.
2014 recommends these patients, as well as T315i-mutated patients in the chronic or accelerated phases, receive allogeneic HCT. 6 HID HCT is standard care for advanced CML patients in China. Therefore, the overall number of HCTs for CML is stable, whereas the proportion of CML patients receiving allogeneic HCT is decreasing continuously.
Another notable trend is that the number of SAA cases undergoing HCT is growing due to new strategies being developed. HID HCT has been considered a potential option in patients with SAA in the absence of an identical sibling donor or URD. 6, 27, 28 The feasibility of HID transplantation was evaluated for treating SAA patients following the failure of previous immunosuppressant therapy in a prospective multicenter clinical trial registered as ChiCTR-ONC-12002107 at http://www.chictr.org.cn/enIndex.aspx. 27 HID HCT, as an upfront therapy, was an effective and safe option for SAA patients with favorable outcomes in experienced centers in a registry-based comparison study. 28 The consideration of cost effectiveness between these two highly expensive treatments, immunosuppressive therapy and HCT, may have a great effect on the future trends.
An important finding in this study was that there were marked differences in donor and stem cell selections from CIBMTR and EBMT with rapid growth of URD or cord blood PBSCs is a priority. In China, HID is the most rapidly growing donor pool, and G-CSF-primed BM combined with PBSCs is popular for use in HID HCT. HID HCT was studied intensively because of the decreasing family size in China. The optimization of protocols and pretransplant risk stratification has helped improve the results of HID HCT. In the new era of 'everyone has a donor', we look for the best among many HID candidates. On the basis of a large sample size and relative consistency of transplant variables, Wang et al. 29 proposed an algorithm for donor selection. This algorithm ranks haplo donor characteristics in the following order: young, male, non-inherited maternal antigen mismatch. Transplants from older mothers and non-inherited paternal antigen-mismatched donors should be avoided. Recently, the relationship between donorspecific anti-HLA antibodies and primary graft failure after un-manipulated HID HCT was investigated in a prospective randomly assigned training and validation sets study. 30 The results suggested that incorporating donor-specific antibodies in the algorithm improved HID selection. 30 The increased numbers of allogeneic HCTs using HID reflect the greater availability of donors and the recognition that HID transplantation provides equivalent safety to related donor transplantation and URD in many conditions including AML, ALL, CML, MDS and SAA. The conclusion that HID HCT can give similar clinical outcomes with MRD and URD is supported by a series of comparative studies listed in Table 2 . 18, 21, 27, 28, [31] [32] [33] [34] [35] [36] [37] The use of HID continues to increase due to its convenience and ready availability without delay. A dramatic increase in the number of HID HCTs performed was observed in 2013, but only a slower increase in MRD, URD and CBT. This was compensated for by an increase in the use of HIDs who are, in some sense, competition for URD and CBT.
The current study has some limitations. Primarily, the survey did not include patient demographics or outcomes, and many other factors. Thus, detailed data are not available. Nevertheless, this survey did highlight trends both in HCT activity and registry in China. The results provide reasonably comprehensive information about the current state of HCT in China, and could be the basis for multicenter retrospective studies of HCT practice and outcomes. The survey results also suggest that clinical decisions could be made based on local experience from clinical trials. Further efforts should be made to obtain detailed information from all centers to create a complete data set.
